Mustang Bio
company
About
Mustang Bio is a clinical-stage biopharmaceutical company .
- 51 - 100
Highlights
Details
- Last Funding Type
- Post-IPO Debt
- Last Funding Money Raised
- $20M
- Industries
- Biotechnology,Pharmaceutical
- Founded date
- Jan 1, 2015
- Number Of Employee
- 51 - 100
- Operating Status
- Active
Mustang Bio is a clinical-stage biopharmaceutical company focused on the acquisition, development, and commercialization of novel cancer immunotherapy products designed to utilize the power of the patient's own immune system to eliminate cancer cells. The products under development are - CD123, CD20, and CS1.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
$22M
Mustang Bio has raised a total of
$22M
in funding over 2 rounds. Their latest funding was raised on
Nov 1, 2021 from a Grant round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Nov 1, 2021 | Grant | $2M | 1 | — | — | Detail |
| Apr 1, 2019 | Post-IPO Debt | $20M | 1 |
Horizon Technology Finance
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
1
2
Mustang Bio is funded by 2 investors.
Horizon Technology Finance
and National Institutes of Health
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Horizon Technology Finance
|
Yes | Post-IPO Debt |
National Institutes of Health
|
— | Grant |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
